Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12065502 Bispecific antibody formulation

Patent 12065502 was granted and assigned to Hoffmann-La Roche Limited on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Hoffmann-La Roche Limited

0

Current Assignee

Hoffmann-La Roche Limited

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Anja Sarah Paulus0

Jonas Fast0

Date of Patent

August 20, 2024

0

Patent Application Number

167506460

Date Filed

January 23, 2020

0

Patent Citations

US Patent 10781257 Bispecific T cell activating antigen binding molecules

0

US Patent 8613919 High concentration antibody and protein formulations

0

US Patent 10155815 Bispecific T cell activating antigen binding molecules

0

US Patent 10781258 Bispecific T cell activating antigen binding molecules

0

Patent Primary Examiner

Kimberly Ballard

0

CPC Code

0

0

0

0

0

0

0

0

...

Patent abstract

This invention relates to a pharmaceutical formulation of a bispecific antibody which binds to carcinoembryonic antigen (CEA) and CD3, a process for the preparation and uses of the formulation.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12065502 Bispecific antibody formulation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool